- Home
- USAP vs DSGN Comparison
USAP vs DSGN Comparison
Compare USAP & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USAP
- DSGN
- Stock Information
- Founded
- USAP 1994
- DSGN 2017
- Country
- USAP United States
- DSGN United States
- Employees
- USAP N/A
- DSGN N/A
- Industry
- USAP Steel/Iron Ore
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- USAP Industrials
- DSGN Health Care
- Exchange
- USAP Nasdaq
- DSGN Nasdaq
- Market Cap
- USAP 417.5M
- DSGN 348.2M
- IPO Year
- USAP N/A
- DSGN 2021
- Fundamental
- Price
- USAP $44.45
- DSGN $5.06
- Analyst Decision
- USAP Hold
- DSGN Hold
- Analyst Count
- USAP 1
- DSGN 3
- Target Price
- USAP $46.00
- DSGN $7.00
- AVG Volume (30 Days)
- USAP 196.2K
- DSGN 220.6K
- Earning Date
- USAP 10-30-2024
- DSGN 03-18-2025
- Dividend Yield
- USAP N/A
- DSGN N/A
- EPS Growth
- USAP N/A
- DSGN N/A
- EPS
- USAP 2.75
- DSGN N/A
- Revenue
- USAP $327,426,000.00
- DSGN N/A
- Revenue This Year
- USAP $18.18
- DSGN N/A
- Revenue Next Year
- USAP N/A
- DSGN N/A
- P/E Ratio
- USAP $16.14
- DSGN N/A
- Revenue Growth
- USAP 24.80
- DSGN N/A
- 52 Week Low
- USAP $17.02
- DSGN $2.25
- 52 Week High
- USAP $45.30
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- USAP 58.45
- DSGN 44.20
- Support Level
- USAP $43.87
- DSGN $3.71
- Resistance Level
- USAP $44.83
- DSGN $6.81
- Average True Range (ATR)
- USAP 0.32
- DSGN 0.49
- MACD
- USAP 0.05
- DSGN -0.14
- Stochastic Oscillator
- USAP 73.97
- DSGN 43.55
About USAP Universal Stainless & Alloy Products Inc.
Universal Stainless & Alloy Products Inc manufactures and markets semi-finished and finished specialty steel products, including stainless steel, nickel alloys, tool steel, and certain other alloyed steels. The company along with its subsidiaries involves melting, remelting, heat treating, hot and cold rolling, forging, machining and cold drawing of semi-finished and finished specialty steels. Its products are sold to service centers, forgers, rerollers, and original equipment manufacturers.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.